
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc. has demonstrated resilience with a 100% contract renewal rate among existing customers, and an increasing trend towards multi-year contracts, suggesting strong commercial momentum in the near future. Management's focus on a capital conservation strategy has led to a reduction in operating expenses, which, combined with anticipated improvements in the hospital contracting process, positions the company for increased revenue growth as hospital partnerships are expected to expand. Additionally, the launch of the next-generation LungFit PH device at the end of 2024 is likely to further enhance their market presence and operational efficiency.
Bears say
Beyond Air Inc's financial outlook remains negative as the company continues to exhibit sluggish revenue trends, reflected in a negative gross margin percentage and a significant cash burn of $13.1 million during the first quarter, leaving the firm with $21.4 million in cash. Additionally, management has lowered its fiscal year 2025 revenue guidance to over $10 million amidst ongoing software upgrade delays that have impacted existing customer engagement, further complicating revenue generation prospects. The company's capital preservation strategy, which includes a 20% reduction in headcount and a narrowed focus on commercial execution, highlights the risks associated with future cash generation and potential reliance on external financing to stabilize operations.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares